The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.

Details

Serval ID
serval:BIB_1228E171873C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Journal
Anticancer research
Author(s)
Stravodimou A., Voutsadakis I.A.
ISSN
1791-7530 (Electronic)
ISSN-L
0250-7005
Publication state
Published
Issued date
09/2020
Peer-reviewed
Oui
Volume
40
Number
9
Pages
4829-4841
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. ER+/HER2- cancers are treated with hormone-based therapies in the adjuvant setting and derive significant survival benefit from these therapies in the metastatic setting. However, hormone resistance develops in most metastatic patients. An increased understanding of the biology of ER+/HER2- breast cancers has led to the development of new therapies for this disease including CDK4/6 inhibitors and PI3K inhibitors. Several other neoplastic processes are targeted by novel drugs in clinical development, addressing cancer vulnerabilities. These include newer ways to block the ER and targeting the HER2 receptors in ER+/HER2- cancers expressing HER2 in low levels not qualifying for clinical positivity. In addition, promising therapeutic options include targeting other surface receptors or their downstream pathways, as well as targeting the apoptotic machinery and boosting the immune response which is initially insufficient in these cancers. A selection of new drugs in advanced development for ER+/HER2- breast cancer will be discussed in this review.
Keywords
Antineoplastic Agents/therapeutic use, Apoptosis/drug effects, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Drug Resistance, Neoplasm/drug effects, Drug Resistance, Neoplasm/genetics, Female, Humans, Mutation, Phosphatidylinositol 3-Kinases/metabolism, Receptor, ErbB-2/antagonists & inhibitors, Receptor, ErbB-2/metabolism, Receptors, Estrogen/antagonists & inhibitors, Receptors, Estrogen/genetics, Receptors, Estrogen/metabolism, Receptors, Fibroblast Growth Factor/antagonists & inhibitors, Receptors, Fibroblast Growth Factor/metabolism, Signal Transduction/drug effects, ER positive, ER targeting, FGFR inhibitors, breast cancer, elacestrant, review, venetoclax
Pubmed
Web of science
Create date
14/09/2020 14:06
Last modification date
26/11/2020 7:24
Usage data